ライフサイエンスコーパス: PI3-kinase

1 tion occurred through the c-Met receptor and PI3 kinase.

2 re sensitive to inhibition of either MAPK or PI3 kinase.

3 nd was insensitive to inhibitors of P2Y12 or PI3 kinase.

4 ransduces BAFFR survival signals via ERK and PI3 kinase.

5 ivation of phospholipase C and, for TLR 2/1, PI3-kinase.

6 n insulin-like receptor, primarily activates PI3-kinase.

7 LRP1 activates cell survival signals such as PI3-kinase.

8 g p110gamma despite the presence of class Ia PI3-kinase.

9 activation of Beclin 1-containing class III PI3-kinase.

10 p110gamma, the catalytic subunit of class Ib PI3-kinase.

11 chemokines, and other agonists that activate PI3-kinase.

12 sing due to blockade of RAS interaction with PI3-Kinase.

13 which is chemotactic and controlled through PI3-kinase.

14 t manner that is reversible and regulated by PI3-kinase.

15 d >500-fold selectivity over closely related PI3 kinases.

16 bind the p85 subunit of phosphoinositide 3 (PI3)-kinase.

17 of the survival kinase, phosphoinositide 3 (PI3)-kinase.

18 y of the other catalytic subunits of class I PI3-kinases.

19 RAS proteins directly activate PI3-kinases.

20 Phospholipase C and PI3 kinases 1 and 2, which are necessary for the activit

21 e activity of phosphatidylinositol 3-kinase (PI3-kinase), a major regulator of Akt.

22 ng a type III PI3 kinase (Vps34), a putative PI3 kinase, a putative mitogen-activated extracellular s

23 duced AChR clusters in cultured myotubes via PI3 kinase acting through GSK3beta.

24 critically dependent on phosphoinositide 3 (PI3)-kinase activation, as administration of a PI3 kinas

25 d Rac activation, superoxide production, and PI3-kinase activation in differentiated HL60 cells.

26 RLIP76 was required for PI3-kinase activation, known to regulate HIF-1, in these

27 , the role of phosphatidylinositol 3-kinase (PI3-kinase) activation in CD28 function has been highly

28 ing Akt via its inositol phosphate kinase or PI3-kinase activities, respectively.

29 n, and the prevention of both WW binding and PI3 kinase activity are required for ErbB4 nuclear trans

30 ized phagosomes did not require p40(phox) or PI3 kinase activity, although superoxide production befo

31 minant-negative forms, but not inhibition of PI3 kinase activity, dramatically impaired EpoR internal

32 Our results identify a novel PI3 kinase activity-independent function of p85 in EpoR

33 Interestingly, Smad3 did not affect PI3 kinase activity.

34 of basolateral trafficking were dependent on PI3 kinase activity.

35 radation in the liver requires both class II PI3-kinase activity and autophagy.

36 their native microenvironment when levels of PI3-kinase activity and DE-cadherin are elevated in NBs.

37 When levels of PI3-kinase activity and/or DE-Cadherin are reduced in NB

38 eration ceases, because growth factor and/or PI3-kinase activity levels become attenuated.

39 Linking levels of PI3-kinase activity to the strength of adhesive attachme

40 tion proteins ULK1, Beclin 1, and ATG14L and PI3-kinase activity.

41 proliferation caused uniquely by loss of its PI3-kinase activity.

42 dependent of dietary nutrient conditions and PI3-kinase activity.

43 er, polarized PKA activation did not require PI3-kinase activity.

44 ne-binding domain, PTB) and does not require PI3-kinase activity.

45 the class III phosphatidylinositol 3-kinase (PI3-kinase) activity of vps34.

46 major product of phosphoinositide 3 kinase (PI3-kinase) activity, is essential for phagocytosis.

47 gnaling effectors phosphoinositide-3 kinase (PI3 kinase), Akt, Raf-1, mitogen-activated protein kinas

48 The phosphatidylinositol-3-kinase (PI3 kinase)-AKT pathway is frequently activated in cance

49 ition of the phosphatidylinositide 3-kinase (PI3 kinase)/AKT pathway, as was the tightly bound fracti

50 argets of the phosphatidylinositol 3-kinase (PI3-kinase)/Akt pathway.

51 We showed previously that the PI3 kinase-Akt pathway downstream of BDNF/TrkB signaling

52 Studies with inhibitors showed that PI3 kinase-Akt-mTOR-p70S6 kinase pathway controlled chan

53 Accordingly, PM-based motogenic signals (PI3-kinase-Akt and PLCgamma1) are amplified, and cell mi

54 iciency did not alter BAFF activation of the PI3-kinase-Akt or NF-kappaB signaling pathways, which ar

55 ng BDNF or TrkB mRNA, and MEK/ERK (U0126) or PI3 kinase/Akt (PI828) inhibitors.

56 rowth factor signaling pathways regulated by PI3 kinase/Akt and MAP kinases with Myc-mediated transcr

57 sure to overcome the defective activation of PI3 kinase/Akt and Raf/MEK/ERK, implicate both Ras effec

58 output of two major oncogenic pathways, the PI3 kinase/AKT and the Rat sarcoma (RAS)/ERK pathways.

59 An applied electric field activated PI3 kinase/Akt in dermal fibroblasts.

60 A similar effect of PI3 kinase/AKT inhibition was observed for mRNAs from bo

61 d site" amino acid substitutions that impair PI3 kinase/Akt or Raf/MEK/ERK activation in bone marrow

62 These results show that the active PI3 kinase/AKT pathway can regulate mRNA export and prom

63 Inhibition of the PI3 kinase/AKT pathway increased the export of poly(A) R

64 rative and antiapoptotic effects include the PI3 kinase/Akt pathway, the MAP kinase pathway and the b

65 m or to mitochondria was not affected by the PI3 kinase/AKT pathway.

66 TG1, two oncogenes that regulate the RB1 and PI3 kinase/AKT pathways, respectively.

67 d-type mice and suggested the involvement of PI3 kinase/Akt signaling components.

68 ssion of Inpp4b and changes in intracellular PI3 Kinase/AKT signaling in follicular granulosa cells.

69 n the phosphorylation and activation of EGFR/PI3 kinase/AKT signaling in hepatocytes.

70 K causes dephosphorylation of members of the PI3 kinase/AKT/mTOR pathway and delays sensitive cells i

71 monstrate activation of macrophage/foam cell PI3-kinase/Akt in atherosclerotic plaques from apolipopr

72 that is blocked by PKA inhibitors but not by PI3-kinase/Akt inhibitors.

73 Here we show that macrophage PI3-kinase/Akt is activated by oxidized low-density lipo

74 d HO-1 mRNA expression through activation of PI3-kinase/Akt pathway without affecting ERK and p38 MAP

75 phosphatase and a negative regulator of the PI3-kinase/Akt pathway.

76 motherapy response in AMkL by regulating the PI3-kinase/Akt pathway.

77 stant, cell lines, an effect mediated by the PI3-kinase/Akt pathway.

78 ibitors radiosensitize tumors with activated PI3-kinase/Akt pathway.

79 The PI3-kinase/Akt signaling pathway activates RalA through

80 gatively regulates the RGC downstream of the PI3-kinase/Akt signaling pathway.

81 rm of atherosclerosis, whereas activation of PI3-kinase/Akt was undetectable in lesions from apoE-nul

82 ellular-signal regulated kinase [ERK] 1/2 or PI3-kinase/Akt) during the early min of reperfusion.

83 ivin expression in Ba/F3 cells downstream of PI3-kinase/Akt.

84 ly an additional mechanism through which the PI3-kinase/Akt/FOXO pathway can modulate Myc function.

85 ze and exhibited an elevated activity of the PI3-kinase/Akt/mTOR pathway, which was associated with a

86 al function in the induction of the type III PI3 kinase and autophagy in response to amyloid beta pep

87 VPS34 encodes the PI3 kinase and is also required for the Vid pathway.

88 pe is mimicked by constitutive activation of PI3 kinase and is rescued by the removal of PDK1 (PDPK1)

89 ng by derepression of the p85beta subunit of PI3 kinase and of Spred1, respectively.

90 lin-induced signaling includes activation of PI3 kinase and protein kinase B (PKB)/Akt.

91 their downstream effectors suggest that Ras/PI3 kinase and Ras/Raf1 pathways contribute to SF stimul

92 RAS-GTP-driven signaling via MAP kinases and PI3 kinases and mitogen-stress-related kinase-1 for NF-k

93 have been proposed to involve predominantly PI3-kinase and BCL-X pathways.

94 signal transduction machinery, but involving PI3-kinase and downstream PH domain proteins, CRAC and P

95 anges require activation of the MAP kinases, PI3-kinase and downstream signalling pathways and are ob

96 the Drosophila retina has demonstrated that PI3-kinase and downstream TOR signalling regulate the ti

97 ers of the cases and included members of the PI3-kinase and homologous DNA repair pathways.

98 n of Pax-2, and decreased phosphorylation of PI3-kinase and MAP kinase in the WD.

99 in turn regulates the key components of the PI3-kinase and nuclear factor-kappaB pathways.

100 s FGF-2 synthesis in corneal endothelium via PI3-kinase and p38.

101 PI3-kinase and PTEN are major positive and negative regu

102 Thus, the prevalence of PI3-kinase and PTEN mutations in cancer may result in pa

103 genes, is correlated with activation of both PI3-kinase and Ras signaling in human prostate tumors an

104 Combinatorial activation of PI3-kinase and RAS signaling occurs frequently in advanc

105 er metastasis in response to coactivation of PI3-kinase and Ras signaling pathways in a genetically e

106 s in prostate tumors that have activation of PI3-kinase and Ras signaling, and therefore, ETV4 repres

107 rough the sequential activations of the p110 PI3-kinases and IPMK.

108 rosophila utilize Phosphoinositide 3-kinase (PI3-kinase) and DE-cadherin to build adhesive contact fo

109 signaling through phosphoinositide 3-kinase (PI3-kinase) and the PI3-kinase-dependent protein serine/

110 confirmed coimmunoprecipitation of erbB2/4, PI3 kinase, and Akt with ET(A), and confocal microscopy

111 The protein powder increased insulinemia, PI3 kinase, and erk phosphorylation but did not affect t

112 orylation of protein kinase C, activation of PI3 kinase, and phosphorylation of Akt.

113 iates with PP2A, YAP, tyrosine kinases, Shc, PI3 kinase, and PLCgamma1.

114 aises active Erk, halts receptor editing via PI3 kinase, and promotes differentiation via Erk, breaki

115 in kinases ERK, JNK, and p38 as well as Akt, PI3 kinase, and RhoA.

116 e marrow cells, which were mediated via ERK, PI3-kinase, and Galphai-Rac1 pathways.

117 h the non-receptor tyrosine kinase c-Src and PI3-kinase, and that treating cells with inhibitors to b

118 Although virus infection activated PI3 kinase, as indicated by AKT activation, its blockage

119 le via a checkpoint response mediated by the PI3 kinases ATM and ATR.

120 Although the DNA damage checkpoint PI3-kinases ATM and ATR localize to telomeres and promot

121 ng molecules, phosphatidylinositol 3-kinase (PI3-kinase) being the best studied of these.

122 ns with switch 2 insertions are impaired for PI3 kinase binding and Akt activation, and are hypersens

123 n of the proximal tyrosine motif interrupted PI3-kinase binding and prevented CD28-dependent phosphor

124 These results suggest that the commonly used PI3 kinase blocker LY 294002 may modulate GlyT1 function

125 egulation of autophagy requires the type III PI3 kinase, but not inhibition of mTORC1, the essential

126 naling pathway, whereas direct activation of PI3-kinase by the proximal tyrosine motif of CD28 is not

127 Inhibition of p110 PI3-kinases by wortmannin prevents IPMK phosphorylation

128 EA1 and Rab5A (early endosomes), Rab7L1, and PI3-kinase C2gamma and PI4-kinase IIIalpha (phospholipid

129 Dermal fibroblasts from p110gamma (a PI3 kinase catalytic subunit) null mice showed significa

130 ts p85alpha and p85beta are dispensable, the PI3-kinase catalytic subunit p110alpha requires interact

131 yeast Candida glabrata Here, we demonstrate PI3-kinase (CgVps34) to be essential for maintenance of

132 tophagy flux by interacting with the Beclin1-PI3 kinase class III protein complex in response to auto

133 n of autophagy molecules such as Beclin1 and PI3 kinase class III resulted in impaired growth of HTLV

134 by the action of the Atg14-containing Vps34 PI3 kinase complex.

135 esion to low-density fibrinogen, whereas PKC/PI3 kinases contribute to platelet spreading on high-den

136 es for both a WW domain and an SH2 domain of PI3 kinase, demonstrated enhanced nuclear translocation

137 ated that LY 294002 and wortmannin inhibited PI3 kinase-dependent Akt phosphorylation in the primary

138 atinocytes differently, albeit using similar PI3 kinase-dependent mechanisms.

139 nophil lifespan (via a NF-kappaB and Class I PI3-kinase-dependent mechanism); and (v) complete abroga

140 apoptosis by promoting Akt activation via a PI3-kinase-dependent mechanism.

141 osphoinositide 3-kinase (PI3-kinase) and the PI3-kinase-dependent protein serine/threonine kinase Akt

142 This occurs through PI3-kinase-dependent regulation of DE-Cadherin-mediated

143 Downstream of PI3-kinase, distinct effectors have opposing roles in re

144 A third PI3 kinase, DNA-dependent protein kinase (DNA-PK), is al

145 mTOR is an evolutionarily conserved PI3-kinase family member that plays a central role in in

146 including Gbetagamma-dependent activation of PI3-kinase gamma and Rac1, could inhibit chemoattractant

147 cule targeting of phosphoinositide 3-kinase (PI3-kinase) gamma catalytic activity is a target of inte

148 onic lethality seen in mice lacking class Ia PI3-kinase, germ-line deletion of p110gamma results in m

149 transport system, organized by agrin through PI3 kinase, GSK3beta, CLASP2, and LL5beta, for precise d

150 totic signaling from its receptor (c-Met) to PI3 kinase --> c-Akt --> Pak1 (p21-activated kinase -1)

151 ignalling through phosphoinositide 3-kinase (PI3-Kinase) has been shown to have an essential role in

152 tein kinase targets and structurally related PI3 kinases, histone deacetylases, poly(ADP-ribose)polym

153 ion of this signaling includes activation of PI3-kinase, IGF1R and Akt, Ca2(+)-sensitive transcriptio

154 esults highlight the importance of the c-Kit-PI3 kinase-IL-6 signaling axis in DCs in regulating T ce

155 We tested the role of PI3 kinase in anode-directed migration of fibroblasts.

156 iety of protocols used to assess the role of PI3 kinase in biological systems, or for achieving optim

157 ances in understanding the roles of class II PI3 kinases in different pathological contexts is leadin

158 eness, but the role of direct RAS binding to PI3-Kinase in this remains uncertain.

159 he action of phosphatidylinositol 3-kinases (PI3 kinases) in the infected cells.

160 itogen activated protein kinases (MAPK), the PI3-kinase induced signalling network and E3 ubiquitin l

161 morphogenesis while both phospholipase C and PI3 kinase inhibition reverse these effects.

162 ulation by PTEN on its own synthesis through PI3 kinase inhibition.

163 2 may modulate GlyT1 function independent of PI3 kinase inhibition.

164 mote glucose uptake, as Akt1(-/-) T cells or PI3-kinase inhibition and RNAi of STAT5 led to defective

165 0S6kinase inhibition nor was it prevented by PI3-kinase inhibition.

166 utophagy, treatment of infected cells with a PI3 kinase inhibitor attenuates autophagy in infected ce

167 cells form Rad52 foci in the presence of the PI3 kinase inhibitor caffeine.

168 s not surprising that the presence of a sole PI3 kinase inhibitor does not prevent inevitable host-ce

169 B. xylophilus with long-chain FAEEs, or the PI3 kinase inhibitor LY294002, promotes LIV formation, w

170 urea (2), an active metabolite of the potent PI3 kinase inhibitor PKI-179 (1), is described.

171 was blocked by the Jak2 inhibitor AG490, the PI3 kinase inhibitor wortmannin, and the phospholipase C

172 LY 294002, a PI3 kinase inhibitor, blocked the GlyT1-mediated glycine

173 3)-kinase activation, as administration of a PI3 kinase inhibitor, wortmannin, reduced Gsk3 phosphory

174 GLUT4 were blocked by pretreatment with the PI3-kinase inhibitor LY294002.

175 Treatment with the PI3-kinase inhibitor PIK-75 similarly inhibited motility

176 Further, a PI3-kinase inhibitor, LY294002, and cytosine arabinoside

177 )] and a specific phosphoinositide 3 kinase (PI3 kinase) inhibitor (LY294,002 [2-(4-morpholinyl)-8-ph

178 l-2-/- cells was enhanced in the presence of PI3 kinase inhibitors 3-methyladenine and Wortmannin and

179 rview on the current development of class II PI3 kinase inhibitors and outline the potential use for

180 d the effects of the phosphatidylinositol 3 (PI3) kinase inhibitors LY 294002 and wortmannin on GlyT1

181 Furthermore, distinct PI3-kinase inhibitors completely abrogated the protectiv

182 Our study suggests that the type III PI3 kinase integrates diverse signals to regulate cellul

183 tween C20 and a lysine in the active site of PI3 kinase is essential to Wm's ability to inhibit this

184 Class III PI3-kinase is not activated by insulin, but the other tw

185 t is unknown whether interaction of RAS with PI3-kinase is required in established tumors.

186 lear, however, which of the three classes of PI3-kinases is required for insulin-stimulated apoB100 d

187 ] products of phosphatidylinositol 3-kinase (PI3-kinase) is an early event in establishing the direct

188 nsulin regulates GLUT4 and FoxO1 through the PI3-kinase isoform p110alpha, although FoxO1 showed high

189 age checkpoint, which is orchestrated by the PI3 kinase-like protein kinases ATR and ATM (Mec1 and Te

190 ponents of the PI3-kinase pathway, including PI3-kinase (LY294002) and mTORC1 (rapamycin), ablated th

191 signaling involvement was determined using a PI3-kinase (LY294002) or Rac1 (NSC23766) inhibitor.

192 ing exposure to small molecule inhibitors of PI3-kinase (LY294002) or TOR (Rapamycin) activity.

193 regulated by HGF and EGF receptors and that PI3 kinase-mediated signaling independent of AKT is a cr

194 Phosphatidylinositol-3-OH kinase (PI3 kinase) mediates cathode-directed migration of kerat

195 hepatic hepcidin synthesis, in part through PI3 kinase MEK/ERK kinase pathways which may be modulati

196 ortening, cellular senescence, activation of PI3 kinase-mTOR signaling, impaired autophagy, mitochond

197 arget of rapamycin (mTOR) blocker RAD001 and PI3-kinase/mTOR blocker NVP-BEZ235.

198 poptosis and triggered the activation of the PI3-kinase/mTOR Complex 1 (mTORC1)/p70 S6-kinase pathway

199 valuated the therapeutic efficacy of a novel PI3-kinase/mTOR inhibitor, PI-103, in established glioma

200 EpoR cytoplasmic domain bind p85 subunit of PI3 kinase on Epo stimulation and individually are suffi

201 tment of AMkL may be improved by integrating PI3-kinase or Akt inhibitors into the chemotherapy of th

202 p110delta subunit of phosphatidylinositol-3 (PI3) kinase (p110(D910A)) secreted lower amounts of IL-6

203 ence that disruption of RAS interaction with PI3-Kinase p110alpha decreases cell motility and prevent

204 linkage analysis: a homozygous stop codon in PI3-kinase p110delta (PIK3CD) and a homozygous frame shi

205 h a combined deficiency of 2 genes products, PI3-kinase p110delta and SKAP, both of which appear to p

206 p85alpha and p85beta regulatory subunits of PI3'-kinase (p85alpha(-/-)beta(-/-)) to precisely define

207 FR and PDGFR was necessary for abrogation of PI3 kinase pathway activity in the mixed population.

208 olecule kinase inhibitors, inhibitors in the PI3 kinase pathway and in the mitogen-activated ERK kina

209 Activation of PI3 kinase pathway is associated with trastuzumab resist

210 on of cell cycle and phosphatidylinositol-3 (PI3) kinase pathway genes and can be reactivated through

211 l partly through the phophostidylinositol 3 (PI3) kinase pathway: inhibiting this path was previously

212 complex and also through phosphoinositide-3 (PI3)-kinase pathway-dependent stabilization of CD154 mRN

213 mice develop PIN, but only in the context of PI3-kinase pathway activation.

214 invasion by ErbB3 requires activation of the PI3-kinase pathway by the ErbB3 receptor.

215 ologic outcome of selectively activating the PI3-kinase pathway in the endometrial epithelium remains

216 The PI3-kinase pathway is commonly activated in tumors, most

217 trate that cell-autonomous activation of the PI3-kinase pathway is sufficient for the initiation of e

218 Epithelial-specific activation of the PI3-kinase pathway is the most common genetic alteration

219 tion from neonatal HSCs did not activate the PI3-kinase pathway or promote HSC proliferation, HSC dep

220 that this reflects developmental changes in PI3-kinase pathway regulation.

221 Impairment of this PI3-kinase pathway results in slow movement under agaros

222 Cell-autonomous activation of the PI3-kinase pathway via biallelic loss of PTEN or activat

223 downstream of PDK1, the master kinase of the PI3-kinase pathway, exhibit deficient neuron production.

224 inhibitors that inactivate components of the PI3-kinase pathway, including PI3-kinase (LY294002) and

225 dult mouse hematopoietic cells activates the PI3-kinase pathway, inducing hematopoietic stem cell (HS

226 nd negative regulators, respectively, of the PI3-kinase pathway, which regulates growth, survival, an

227 activated by growth factor signaling via the PI3-kinase pathway.

228 mplex, and prevented tTG from activating the PI3-kinase pathway.

229 The MAP kinase and PI3 kinase pathways have been identified as the most com

230 rved activation of nuclear factor-kappaB and PI3-kinase pathways in response to APRIL in both cyclin

231 ependent induction of neurogenesis depend on PI3 kinase/phospho-Akt signaling.

232 hosphorylated sites on PKMzeta, we show that PI3-kinase (phosphoinositide 3-kinase), CaMKII (Ca2+/cal

233 The SH3 domain of the PI3 kinase (PI3-SH3 or PI3K-SH3) readily aggregates into

234 the ECM, promoted focal adhesions, enhanced PI3 kinase (PI3K) activity, and induced the invasion of

235 or absence of pharmacological inhibition of PI3 kinase (PI3K) and Akt signalling using wortmannin.

236 g CD19 co-receptor activation and subsequent PI3 kinase (PI3K) signaling.

237 involving focal adhesion kinase-1 (FAK) and PI3 kinase (PI3K)-dependent Akt activation.

238 llowing PDGF stimulation, without effects on PI3-kinase (PI3K) activity.

239 xpression and cell-cycle progression through PI3-kinase (PI3K) and beta-catenin signaling.

240 bits the Hippo pathway through activation of PI3-kinase (PI3K) and phosphoinositide-dependent kinase

241 Coordinated regulation of PI3-kinase (PI3K) and the tumor suppressor phosphatase a

242 that mutations in critical genes within the PI3-kinase (PI3K) pathway are not functionally equivalen

243 The PI3-kinase (PI3K) pathway regulates many cellular proces

244 The major participants of the Ras/ERK and PI3-kinase (PI3K) pathways are well characterized.

245 associates with G2/M-arrest, inactivation of PI3-kinase (PI3K) signaling, and induction of apoptosis.

246 To test this, we targeted class II and III PI3 kinases (PI3Ks) in an MTM1-deficient mouse model.

247 dentify a new pathway based on the class III PI3-kinase (PIK3C3), ankyrin-B (AnkB), and dynactin, whi

248 r activating mutations of phosphoinositol-3 (PI3) kinase (PIK3CA) may be associated with trastuzumab

249 and MEF2B), NF-kappaB (CARD11 and TNFAIP3), PI3 kinase (PIK3CD, PIK3R1, and MTOR), B-cell lineage (I

250 Consistent with phosphoinositide 3 (PI3) kinase playing a role in autophagy, treatment of in

251 Therefore, leptin through a Jak2-PI3 kinase-PLCgamma pathway activates TRPC channels, and

252 inhibitor of phosphatidyl inositol 3-kinase (PI3-kinase) prevented induction of ATG5 and activation o

253 phate (PIP(3)), formed by the p110 family of PI3-kinases, promotes cellular growth, proliferation, an

254 lin thus plays a role in restraining RAS and PI3-kinase promotion of cell motility and potentially tu

255 death response, because inhibitors of Akt or PI3 kinase protect cells from death.

256 By opposing PI3-kinases, PTEN inhibits proliferation and promotes di

257 d that Wnt5a stimulates phagocytosis through PI3 kinase-Rac1 and lipid-raft-dependent processes.

258 at CIN translocates to the leading edge in a PI3-kinase-, Rac1-, and cofilin-dependent manner after E

259 These results demonstrate that the PI3 kinase/Rap1 pathway is intrinsically impaired in pla

260 Although the PI3-kinase regulatory subunits p85alpha and p85beta are

261 y proteins and the p85 regulatory subunit of PI3-Kinase, respectively.

262 ression induces the sequential activation of PI3 kinase, Rho and ROCK, leading to activation of Myc t

263 Class I PI3-kinases signal downstream of receptor tyrosine kinas

264 AIA circuit and AGE-1, an insulin-regulated PI3 kinase, signal to AWC to drive nuclear enrichment of

265 PI3 kinase signaling also increases Wnt signaling via ph

266 d that GDF10 downregulated PTEN, upregulated PI3 kinase signaling and induced specific axonal guidanc

267 Myocd was activated by PI3 kinase signaling and its downstream target Nkx2.5.

268 nd activation of Akt1, a key molecule in the PI3 kinase signaling pathway.

269 iferation slows because of decreased insulin/PI3 kinase signaling, resulting in nuclear localization

270 Alk maintains PI3-kinase signaling during NR as its ligand, Jelly bell

271 val through a novel mechanism that activates PI3-kinase signaling events, thus highlighting tTG as a

272 ding genetic evidence supporting the role of PI3-kinase signaling in these processes in E. histolytic

273 We tested the hypothesis that ErbB3-mediated PI3-kinase signaling is critical for heregulin-induced m

274 and is mediated by GluR2-lacking AMPARs and PI3-kinase signaling.

275 ical role for phosphatidylinositol 3-kinase (PI3-kinase) signaling in cell proliferation that is supp

276 t human UCC that have high levels of Wnt and PI3 kinase signalling may be responsive to mTOR inhibiti

277 PDGF signalling activates the PI3 kinase signalling pathway in vivo and activation of

278 We further demonstrate expression of PI3-kinase signalling components and active PKB and TOR

279 In contrast, stimulating PI3-kinase signalling did not increase neuron production

280 PIP3 phosphatase that antagonizes oncogenic PI3-kinase signalling.

281 or, thought to primarily act by antagonizing PI3-kinase signalling.

282 ipocytes demonstrated that insulin-activated PI3-kinase signals to GLUT4 primarily through Akt2 kinas

283 Inhibition of PI3 kinase similarly exacerbated cisplatin-induced apopt

284 observed that phosphatidylinositol-3-kinase (PI3 kinase), Src family kinase (SFK), and downstream pro

285 significantly reduced phosphorylation of the PI3 kinase substrate Akt, and have reduced activation of

286 Although the oncogenic potential of the PI3-kinase subunit p110alpha requires its mutational act

287 Phosphoinositide kinases such as PI3-kinase synthesize lipid second messengers that contr

288 ctor 3, a subunit of protein phosphatase 2A, PI3 kinase target of rapamycin 1) scaffold of protein ph

289 implications for the clinical deployment of PI3' kinase-targeted therapies.

290 stradiol triggers a nongenomic activation of PI3 kinase that results in enhanced glutamate release fr

291 rm in liver, we now show that it is class II PI3-kinase that is required for insulin-stimulated apoB1

292 Second, BDNF/TrkB signaling activates PI3-kinase that promotes anterograde transport of TrkB i

293 hyperinsulinaemia on the liver, mediated by PI3 kinase, though consensus on the downstream effectors

294 h factors and cytokines inhibit the type III PI3 kinase through multiple pathways, including the MAPK

295 also stimulates an IGF1 receptor (IGF1R) to PI3 kinase to AKT to GSK-3beta pathway required for acti

296 n, and differentiation, including a type III PI3 kinase (Vps34), a putative PI3 kinase, a putative mi

297 fragments but not for parental cells, while PI3 kinase was essential for the direction sensing of wh

298 s upstream of the activation of the type III PI3 kinase, which is critical for the initiation of auto

299 induction of GRP78 and CHOP, suggesting that PI3-kinase, which is known to mediate ER stress-induced

300 ed) and ATR (ATM and Rad3-related) are large PI3 kinases whose human mutations result in complex synd